Total medical devices private equity deals worth $6.7bn were announced globally in Q3 2022, with Bain Capital’s $3.12bn deal with Evident’s being biggest investment, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 167.6% over the previous quarter and a drop of 22.03% when compared with the last four-quarter average, which stood at $8.58bn.
Comparing private equity deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $3.34bn. At the country level, the US topped the list in terms of deal value at $3.33bn.
In terms of volumes, North America emerged as the top region for medical devices industry private equity deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of private equity deals activity in Q3 2022 the US with 11 deals, followed by the Germany with four and France with two.
In 2022, at the end of , private equity deals worth $12.61bn were announced globally across the medical devices industry, marking a decrease of 20.9% year on year.
private equity deals in medical devices industry in Q3 2022: Top deals
The top five medical devices industry private equity deals accounted for a 94.6% share of the overall value during Q3 2022.
The combined value of the top five medical devices private equity deals stood at $6.33bn, against the overall value of $6.7bn recorded for the quarter.
The top five medical devices industry deals of Q3 2022 tracked by GlobalData were:
1) Bain Capital’s $3.12bn private equity deal with Evident
2) The $1.54bn private equity of Meridian Bioscience by SD Biosensor and SJL Partners
3) Patient Square Capital’s $1.25bn private equity deal with Hanger
4) The $250m private equity of Adaptive Biotechnologies by Orbimed Advisors
5) HartBeat Ventures, North Castle Partners and Rx3 Ventures’s $165m private equity deal with Theragun